The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

CSL has received approval from the EC for Andembry (garadacimab) to prevent recurrent attacks of HAE in patients aged 12 ...

CSL Seqirus, the vaccination segment, was affected by low influenza vaccination rates in the US, dragging down overall ...

CSL has reported a 7% net profit rise for the December half, with its blood-derived products offsetting weak flu vaccination ...

CSL's latest dividend should be turning investors' heads... The post Everything you need to know about the latest CSL ...

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity? The post What are brokers saying about ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

This was the real deal. After I got going, I even started feeling a little dizzy and honestly I thought I might just pack it ...

The CSL Ltd (ASX: CSL) share price will be watched closely today after the biotech giant released its half year ...

CSL’s vaccine division is suffering as Americans turn away from flu vaccinations, with a “very severe” influenza season ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.